Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549


Schedule 14A Information


...

Related Keywords

United States ,Washington , ,Lineage Cell Therapeutics Inc ,Exchange Act ,Securities Exchange ,Statement Pursuant ,Securities Exchange Act ,Commission Only ,Material Pursuant ,Cell Therapeutics ,Its Charter ,Filing Proxy Statement ,Filing Fee ,Exchange Act Rules ,Markets ,